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Abstract
Author Manuscript

It is commonly accepted that brain phospholipids are highly enriched with long chain
polyunsaturated fatty acids (PUFAs). However, the evidence for this remains unclear. We used
HPLC-MS to analyze the content and composition of phospholipids in rat brain and compared it to
the heart, kidney, and liver. Phospholipids typically contain one PUFA, such as 18:2, 20:4, or 22:6,
and one saturated fatty acid, such as 16:0 or 18:0. However, we found that brain phospholipids
containing monounsaturated fatty acids in the place of PUFAs are highly elevated compared to
phospholipids in the heart, kidney, and liver. The relative content of phospholipid containing
PUFAs is ∼60% in the brain whereas it is over 90% in other tissues. The most abundant species of
phosphatidylcholine (PC) is PC(16:0/18:1) in the brain, whereas PC(18:0/20:4) and PC(16:0/20:4)
are predominated in other tissues. Moreover, several major species of plasmanyl and plasmenyl
phosphatidylethanolamine are found to contain monounsaturated fatty acid in the brain only.
Overall, our data clearly show that brain phospholipids are the least enriched with PUFAs of the
four major organs, challenging the common belief that the brain is highly enriched with PUFAs.
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Introduction
It is commonly stated that the brain is highly enriched with polyunsaturated fatty acids
(PUFAs) [1-3], implying that the brain contains higher amounts of PUFAs than other tissues
[4, 5]. Furthermore, the high content of PUFAs has been proposed to be responsible for the
high vulnerability of the brain to ischemia/reperfusion injury [6-8]. However, little evidence
has been provided to support the high enrichment of PUFAs in the brain.
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A majority of cellular fatty acids are esterified to phospholipids [9, 10]. Phospholipids are
composed of a diacylglycerol moiety attached to a phosphate group, which in turn is
connected to various head groups. Two acyl chains derived from fatty acids are attached to
the first and the second carbons of the glycerol moiety, denoted as the sn-1 and sn-2
positions, respectively. Typically, saturated fatty acids or monounsaturated fatty acids
(MUFAs) are present at the sn-1 position and PUFAs, such as 20:4, and 22:6, at the sn-2
position of phospholipids [11-13]. Phospholipids containing MUFAs at the sn-2 position are
also found. The relative content of species containing PUFAs and species containing
MUFAs at the sn-2 position determine the abundance of PUFAs in a tissue. However,
different combinations of the head groups and the acyl chains give rise to numerous isobaric
and isomeric species, which make analysis of phospholipids highly challenging.
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Due to this challenge, analyses of phospholipids are often focused on specific classes or
species of phospholipids [14-16]. Moreover, the acyl chain composition is often examined
following trans-esterification [17-20]. These analyses discovered an abundance of 18:1 and a
lack of 18:2 in brain phospholipids [21, 22]. However, the limitations of the transesterification method, the low recovery of fatty acids from plasmalogens [14] and the loss of
information on the original molecular structure, prevented capturing many key aspects of
phospholipids.
Previously, we developed a normal-phase HPLC-MS method for comprehensive analysis of
phospholipids [21]. The method includes extraction of lipid mixtures and separation of the
phospholipid fraction using solid-phase extraction. Class separation by normal-phase HPLC
prior to MS analysis allows the generation of full spectra of each class of phospholipid. The
full spectra are particularly useful for comparing the molecular composition of each class of
phospholipids between different samples.
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Using this established HPLC-MS method, we analyzed the content and composition of
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS),
phosphatidylglycerol (PG), phosphatidylinositol (PI), and cardiolipin (CL) from the brain,
heart, kidney, and liver. We also analyzed the content of lysophospholipids and free fatty
acids to validate our sampling procedure and to support our conclusion. This thorough
analysis revealed that the brain is least enriched with PUFAs of the four organs examined in
this study.
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Materials and Methods
Chemicals and materials
“Reagent-grade chemicals and HPLC-grade solvents were purchased from major
commercial suppliers (Fisher Scientific and Sigma Aldrich). Standard phospholipids,
PC(16:0/16:0), PE(16:0/16:0), PG(16:0/16:0), PI(16:0/18:1), PS(16:0/16:0), CL(18:2)4,
were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 1,2-Dipalmitoyl-snglycero-3-phospho-N-methylethanolamine (PME), the internal standard, was purchased
from Santa Cruz Biotech (Santa Cruz, CA). Pre-packed silica gel SPE columns were
purchased from Biotage (Charlotte, NC).
Animals
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The experimental protocol was approved by the Institutional Animal Care and Use
Committee. Adult male Sprague–Dawley rats (weight 465–530 g, Charles River Production,
Wilmington, MA) were anesthetized with 4% isoflurane and sacrificed by decapitation to
harvest the brain, heart, kidney, and liver. Rats were maintained under a 12-h light/dark cycle
with free access to food and water and used without starvation. The tissues were
immediately pulverized in liquid nitrogen and stored at -80 °C until analyzed.
Extraction of Phospholipids
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Extraction and separation of phospholipids was performed as previously reported [23, 24].
Briefly, ∼ 1 mg of homogenized tissue was treated with 950 μL of chloroform:methanol
(2:1, v:v) solution containing butylated hydroxytoluene (2 mM) and 50 μL of potassium
phosphate buffer (100 mM, pH 7.4). The organic solution was added first to inactivate any
enzymatic reaction that may facilitate the hydrolysis of phospholipids. Phospholipid
mixtures were separated using solid-phase extraction [23] and reconstituted in 200 μL of
isopropanol:t-butyl methyl ether:ammonium formate (34:17:5, v:v:v) solution. For HPLCMS analysis, 20 μL phospholipid mixture was injected into the HPLC.
Normal-phase HPLC-MS and MS/MS
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The HPLC conditions for separating each class of phospholipids were reported previously
[23]. A nucleosil diol column (5 μm, 3×250 mm) (Macherey-Nagel, Duren, Germany) was
used. Eluent A contained isopropanol:t-butyl methyl ether:ammonium formate (34:17:5,
v:v:v) and eluent B contained methanol. Aqueous ammonium formate was prepared by
dissolving 295 mg of ammonium formate and 1.9 mL of formic acid in 50 mL of water. The
gradients used for the 40 min chromatogram were as follows: 100 % A for 20 min, 100% A
to 20% A over 6 min, 20% A for 8 min, 20% A to 100% A over 1 min, and hold 100% A for
5 min. The flow rate was 0.3 mL/min and the column temperature was 30°C. MS and
MS/MS data were collected using a Thermo LTQ XL spectrometer (Thermo Scientifics, San
Jose, CA) operated in the negative ion mode.
Analysis of molecular species in each class of phospholipids
The content of each class of phospholipids was expressed as a mole fraction of the total
phospholipids. Concentrations of individual classes were determined using standard curves
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and an internal standard as previously reported [23]. Standard curves were generated using
the standard phospholipids with PME as an internal standard. The concentration of PE
includes both diacyl PE and PE plasmalogens (PEP), which contain an ether linkage at the
sn-1 position. Species between diacyl PE and PEP were distinguished based on their
molecular weights and fragmentation patterns by MS/MS [25]. The concentrations of PE
and PS in brain tissue were extrapolated from the standard curve.The abbreviations
previously described for ether alkyl chains of PEP were used [25].
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The content of individual species within a class was calculated from the area of M0 and M1
peaks using the Quan Browser in Xcalibur Version 2.2 software [26]. The content of each
species of phospholipid was expressed as a percentage of total content of the class of
phospholipid. We only included species, whose relative content is greater than 1% of the
total phospholipid content in each class. Assignment of individual species in each class of
phospholipids was made based on retention time and MS and MS/MS analyses [23]. If a
peak contains more than one major isomeric species (over 10% of the total peak intensity),
the area was corrected based on the relative abundance determined by MS/MS. The relative
intensity of CL and PS species was calculated based on the relative intensity of each peak
compared to total CL and PS peaks identified. The isotope abundance and the peak ratio of
sodium adduct of individual species were calculated from authentic standards purchased
from Avanti Polar Lipids. All data are presented as mean ± standard deviation.
Measurement of free fatty acids
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To measure free fatty acids, 20 mg homogenized tissue were extracted in 500 μL of
methylene chloride: methanol: isopropanol 25:65:10 (v/v/v), with 50 μg/mL butylated
hydroxytoluene. UPLC (Ultra-performance LC) was performed using a 1.8 μm particle 100
× 2.1 mm id HSS T3 column (Waters, Milford, MA) coupled to a quadrupole time-of-flight
(TOF) mass spectrometer (AB SCIEX, TripleTOF 5600) operated in information-dependent
MS/MS acquisition mode. The LC and MS conditions were as previously described [27].
The quantification of free fatty acids was performed using MutliQuant Software version
3.0.2 (SCIEX), based on the accurate masses and retention times of each fatty acid.

Results
Concentration of phospholipids
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Ion chromatograms of individual classes of phospholipids from heart tissue separated by
normal-phase HPLC are shown in Fig. S1. The retention time of each class of phospholipids
is similar to the previous reports [23, 26]. The concentrations of individual classes of
phospholipids are shown in Table 1. PE, including diacyl PE and PEP, is the most abundant
class of phospholipids in the brain, heart, and kidney, accounting for 55% of the total
phospholipid content in the brain, 49% in the heart, and 48% in the kidney. PC is the second
most abundant, making up 31%, 38%, and 35% of total phospholipids in the brain, heart and
kidney, respectively. In the liver, PC is the most abundant species, contributing 48% of the
total membrane phospholipids, while PE contributes 35%. The lower content of PE in the
liver compared to other tissues is due to the minimal amount of PEP found in the liver. PS is
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another major class in the brain, accounting for ∼8%. In the kidney and liver, PI is the third
abundant class accounting for ∼ 10% and 13% of total phospholipids, respectively.
Molecular composition of PE
The mass spectra of PE including diacyl PE and PEP from the brain, heart, kidney, and liver
are shown in Fig. 1, and the molecular structures of the major species determined by MS/MS
are listed in Table 2. Most MS peaks are composed of one dominant species with more than
90% of the peak intensity. If the relative content of minor isomeric species is more than 20%
of the major isomers, these minor species are also noted in Table 2. Fig. 2 shows the
calculated mole percentages of the major species of PE as described in the material and
methods section. We provide the relative contents of individual species for an easy
comparison of phospholipid profiles between tissues. However, the relative contents can be
readily converted to absolute concentrations using the values provided in Table 1.

Author Manuscript
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In brain and heart tissue, PE(18:0/22:6) and PE(18:0/20:4) are the most abundant species,
accounting for 11% and 8% in the brain (Fig. 2a), respectively and 20% and 16% in the
heart (Fig. 2b), respectively. In the kidney, arachidonic acid containing species,
PE(18:0/20:4) and PE(16:0/20:4), account for 28% and 9% respectively (Fig. 2c). In the
liver, one dominant species, PE(18:0/20:4), accounts for 30% of total PE. Other major
species, PE(18:0/22:6), PE(16:0/20:4), and PE(18:0/22:6), also make up a substantial
portion of PE in the liver (Fig. 2d). Interestingly, brain PE is also comprised of species
containing MUFAs, such as PE(18:0/18:1) and PE(18:1/18:1), whereas these species are
negligible in other tissues. Since PE(18:1/18:1) found in the brain has the same molecular
weight (m/z 743) as PE(18:0/18:2) found in other tissues, we provide MS/MS spectra of the
nominal peak at 743 as an example to compare the structure of the PE species between brain
and other tissues (Fig. 3). In the brain, the peak at 281 corresponding to 18:1 and the peak at
478 corresponding to octadecenoyl glycerol confirm the structure as PE(18:1/18:1) (Fig. 3a).
In the heart, the peaks at 279 and 283 corresponding to free fatty acids 18:2 and 18:0,
respectively, and the peak at 480 corresponding to octadecanoyl glycerol confirm the
structure as PE(18:0/18:2) (Fig. 3b). The MS/MS spectra of the MS peak at 743 in the
kidney and liver are the same as the heart. Overall, most major PE species contain PUFAs,
such as 22:6 and 20:4, and the relative content of these species are not higher in the brain.
Molecular composition of PEP
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PE contains a substantial amount of plasmalogens (Fig. 4), which are known to be enriched
with PUFAs. The overall concentration of PEP is the highest in the brain. The major species
of PEP contain PEP(16:0/20:4), PEP(18:0/20:4), PEP(16:0/22:6), and PEP(18:0/22:6). In
addition to these PUFA containing species, significant levels of PEP species containing 18:1
at the sn-2 position are present in brain tissue as well (Fig. 4a). Interestingly,
PEP(16:0/18:1), PEP(18:1/18:1), and PEP(18:0/18:1) account for 20% of the total PE
content, which is similar to the relative abundance of the five major PEP species containing
PUFAs (26%) (Fig. 4a).
In the heart, the major species of PEP, such as PEP(16:0/20:4), PEP(16:0/22:6),
PEP(18:0/20:4), and PEP(18:0/22:6), all contain long chain PUFAs (Fig. 4b). These species
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account for ∼26% of the total PE in heart tissue. A similar pattern is observed in the kidney,
but with less overall PEP content (Fig. 4c). The relative content of PEP of total PE is 19% in
kidney tissue. The kidney also contains a detectable amount of species containing MUFAs,
such as PEP(16:0/18:1). Liver contains a dramatically lower content of PEP, accounting for
2% of total PE in liver tissue (Fig. 4d). As was seen in the profile of PE, only brain PEP is
comprised of significant amounts of species containing MUFAs.
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We also show an example of MS/MS spectra a PEP species with molecular weight of 701
from the brain and kidney (Fig. 3c and d). In the brain, the peak at 436 corresponding to
hexadecenyl glycerol and the peak at 281 corresponding to 18:1 confirm the structure as
PEP(16:0/18:1) (Fig. 3c). The peak at 418 is the dehydrated form of the peak at 436 and the
peak at 255 is from 281-CO2. The same peaks at 436 and 281 in the kidney show that the
PEP(16:0/18:1) in the major species is under the MS peak at 701 (Fig. 3d). In addition, the
peak at 438 corresponding to hexadecanyl glycerol and the peak at 279 corresponding to
18:2 confirm the coexistent of plasmanyl PE (16:0/18:2) as a minor species of the same MS
peak in the kidney (Fig. 3d).
Molecular composition of PC
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The mass spectra of PC from heart and brain tissues are shown in Fig. 5 and the
concentrations of major species of PC determined by MS/MS are shown in Fig. 6.
Interestingly in the brain, the most abundant species is PC(16:0/18:1) (Fig. 6a). In addition,
species containing saturated fatty acids or MUFAs, such as PC(16:0/16:0), PC(18:1/18:1)
and PC(18:0/18:1), are also abundant. These four species together account for ∼ 54% of the
total PC content in brain tissue, which is significantly higher than ∼15% of the content of
major PUFA-containing species combined. Again, PC species containing 18:2 are also
negligible in brain tissue (Fig. 6a).
In the heart, PC species containing 20:4, PC(16:0;20:4) and PC(18:0;20:4), are the two
major species, while species containing 22:6 are also abundant (Fig. 6b). Kidney tissue
includes multiple major species, such as PC(16:0/18:2), PC(16:0/20:4) and PC(18:0/20:4) as
well as MUFA containing species (Fig. 6 c). Liver tissue also contains PC(16:0/18:2),
PC(16:0/20:4) and PC(18:0/20:4) as a major PC species. It is notable that no considerable
amounts of PC containing MUFAs are observed in the liver. Overall, Fig. 5 and 6 show that
PC in the brain contains much higher amounts of MUFAs than other organs and liver PC is
most dominated with PUFAs.
Molecular composition of PS
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Mass spectra of PS are shown in Fig. 7 and the concentrations of major species of PS are
shown in Fig. 8. In the brain, two major species of PS are the PS(18:0/22:6) and
PS(18:0/18:1), which account for 51% and 26% of the total PS content, respectively. In the
brain, a total of 65% PS contains PUFAs whereas over 90% of PS contains PUFAs in other
tissues. The most abundant species of PS is PS(18:0/22:6 in the brain and heart and
PS(18:0/20:4) in the kidney and liver. PS species containing 18:2 is not detectable in the
brain, but readily detectable in other organs.
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The MS spectra of PG and PI are shown in Fig. S2 and S3 and the concentrations of
individual species of PI and PG are shown in Fig. 9. The molecular compositions of PI and
PG are similar between tissues that PI and PG each has one dominant species, PI(18:0/20:4),
and PG(18:0/18:1), respectively. Major species of PI only contains PUFAs, whereas PG is
predominated with MUFAs. As was seen in other classes of phospholipid, PI and PG species
containing 18:2 are negligible in the brain.
Composition of CL
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MS spectra of CL are shown in Fig. 10. Fig. 10a shows the MS spectrum of CL from brain
tissue. The CL composition in the brain is highly diverse and markedly differs from its
composition in the heart, kidney, and liver (Fig. 10 b-d). The peak at 1448 corresponding to
tetra-linoleoyl CL, noted as CL(18:2)4 is the major species in the heart, kidney, and liver as
commonly observed [28] In the kidney and liver, the enhanced peaks at 1450 and 1472 show
that CL(18:2)3(18:1) and CL(18:2)3(20:4) are also abundant. CL(18:2)4 accounts for 83% of
the total CL content in the heart, 48% in the kidney, and 45% in the liver. However, the peak
at 1448 in brain is an only minor peak (Fig. 10a). Moreover, the MS/MS spectra revealed
that the peak 1448 is comprised of several isomeric species (Fig. S4). Considering the
relative peak intensity of 1448 by MS and the number of isomers by MS/MS, we conclude
that CL(18:2)4 is less than 1% of the total CL content in the brain. MS/MS analysis also
shows that most CL MS peaks are comprised of multiple isomers. Therefore, the total
number of CL species in the brain should be several times more than the number of the
peaks shown in the MS spectrum (Fig. 10a). Due to this enormous number of species,
characterization of CL in the brain is difficult to achieve.
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Content of lysophospholipids and free fatty acids
Several species of lysoPC, lysoPE, and lysoPI are detected from whole tissue. Fig. S5 shows
the relative peak area of individual species of lysophospholipids compared to the peak area
of the corresponding class of phospholipids. The common species contain 16:0 or 18:0 as
these are the common fatty acid at the sn-1 position of PE and PC. Consistent with the high
abundance of 18:1 in brain tissue, lysoPE and lysoPI species containing 18:1 are readily
detectable in brain tissue.
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Fig. S6 shows the relative content of free fatty acids from 20 mg of each tissue. Since the
contents of free fatty acids are estimated based on their peak areas, the data may not be
appropriate to compare the levels between fatty acids, however, can be used to compare each
fatty acid level between tissues. The data clearly show that the levels of free fatty acids in the
brain are not higher than in other tissues. The amount of 16:0 is the most abundant in liver
tissue compared to in other tissues. The level of 18:0 is similar in all tissues. Compared to
the liver, similar levels of 20:4 and 22:4 are detected in the brain, but all other PUFAs,
including 22:6, are higher in the liver. It is also notable that the brain contains a much lower
content of 18:2 compared to other tissues, consistently with the lack of phospholipid species
containing 18:2 in this tissue. Overall, the results from lysophospholipids and free fatty acids
confirm that there is no significant decomposition of phospholipids from the tissues during
sampling procedures that may interfere with phospholipid analysis.
Mol Cell Biochem. Author manuscript; available in PMC 2019 May 01.
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Discussion
Brain phospholipids are least enriched with PUFAs
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Although it is commonly cited that the brain phospholipids are highly enriched with PUFAs
[29], the evidence for this is limited. Here, we show that the brain has the lowest mole
fraction of PUFA-containing phospholipid species (Fig. 11). The content of overall PUFA
containing species is ∼60% of total phospholipid in the brain, whereas it is over 90% in the
heart and kidney and ∼ 95% in the liver. Consequently, the concentrations of PUFAcontaining phospholipids per mg tissue are also lower in the brain than in the liver. One may
argue that PUFAs are enriched in a special area of brain. In fact, fatty acid composition
differs depending on the areas of the brain [30, 31], but the difference is not sufficient to
make an area of the brain more enriched with PUFA than the heart, kidney, or liver. Overall,
our results are not consistent with the common belief that the brain is highly enriched with
PUFA.
Typical phospholipids in mammalian tissues contain PUFAs at the sn-2 position and
saturated fatty acids at the sn-1 position. Phospholipids containing MUFAs at the sn-2
position are also found, but to a much lesser extent. Therefore, almost every tissue is
enriched with PUFAs, but the abundance of PUFAs has been emphasized only in the brain.
Consequently, it is believed that the PUFA content in brain phospholipids is higher than in
other tissues [4, 5]. Furthermore, the high content of PUFAs, such as 20:4 and 22:6, is
hypothesized to be a major factor responsible for the vulnerability of the brain to ischemia/
reperfusion injury [6-8, 10, 32].
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Our result that brain phospholipids are least enriched with PUFAs of the four organs does
not support this hypothesis. However, the finding does not rule out potential roles that
PUFAs play in ischemic brain damage. Along with other alterations, such as glutamatergic
dysregulation [33], PUFAs may be an important mediator in brain damage. It may be not the
amount of PUFAs but the cellular conditions of the brain that facilitate PUFA-mediated
pathways that may be a contributing factor to the vulnerability of the brain. In this light,
lowering the PUFA content in membrane phospholipids may be the self-regulation of the
brain to protect itself from ischemia. Consistent with this, the brain phospholipid is less
responsive to the PUFA content in diets than other tissues [34, 35].
HPLC-MS analysis of phospholipid
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Due to the existence of numerous isobaric and isomeric species, quantitation of
phospholipids is challenging. Various methods have been applied to quantify phospholipids,
however, the results differ depending on the methods used [20, 36-39]. Since the
development of electrospray ionization, mass spectrometry is the most common method
used to analyze phospholipids [40-42]. Differential ion mobility spectrometry has also
become available and is a promising technique for the differentiation of isomers with or
without silver ion adduction; however, it is limited to only a few number of MS methods
[43].
We used normal-phase HPLC-MS for this study. Normal phase-HPLC separates
phospholipids by class based on their retention times [23].This class separation provides a
Mol Cell Biochem. Author manuscript; available in PMC 2019 May 01.
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full mass spectrum for each class of phospholipid (Fig. 1, 5, 7, and 10). Identification of a
species by MS and MS/MS compared with the mass of the species in these full spectra
reduces chances for false assignments and omission of significant species. In addition, the
concentration of each phospholipid species calculated using automated methods can be
cross-validated by comparing the calculated values with the intensities of the corresponding
peaks in this full spectrum. For example, the concentrations of PE(16:0/20:4) and
PE(16:0/20:4) presented in Fig. 2d can be matched with the peaks at 766.8 and 738.8 in Fig.
1d, respectively. With fully validated sampling and quantitation procedures [23], the normal
phase HPLC-MS method is shown to be advantageous for comparing phospholipid profiles
between multiple tissues.
The lack of 18:2 in brain phospholipids including CL
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The absence of species containing 18:2 in brain phospholipids has been reported previously
[22]. It is interesting, however, that the brain limits the usage of 18:2 even for the synthesis
of CL. In mitochondria, the final structure of CL is determined by the remodeling step,
which preferentially incorporates 18:2 into CL [44, 45]. Consequently, CL(18:2)4 is often
found to be the dominant species in most mammalian tissues [46]. It seems that the relative
abundance of fatty acids is also an important factor in the selection of fatty acids for CL
remodeling. Limiting the usage of 18:2 for the synthesis of CL may have caused the
incorporation of more freely available fatty acids into CL, resulting in the highly diverse CL
composition observed in the brain. This argument is supported by the fact that CL
composition is readily affected by the fat contents in the diet [47-49]. This unique CL
composition suggests that at least for brain mitochondria, neither the symmetry of CL nor
preserving CL(18:2)4 is important. This explains why brain function is not affected in Barth
syndrome patients, who have a defective metabolism for the use of 18:2 for CL.
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In conclusion, unlike the common belief that brain is highly enriched with PUFAs, we have
demonstrated that brain phospholipids contain lower contents of PUFAs than phospholipids
in the heart, kidney and liver. The mole fraction of phospholipids containing PUFAs in the
brain is ∼60%, which is significantly lower than over 90% found in other organs. This low
PUFA content is due to high content of 18:1, particularly in PC, PEP, and PS. Overall, it is a
unique feature that brain phospholipids contain significant amounts of MUFAs, making
brain phospholipid least enriched with PUFAs of the four major organs.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

MS spectra of PE from brain (A), heart (B), kidney (C), and liver (D) tissues. Major species
of diacyl and plasmenyl PE in heart, kidney, and liver tissues contains PUFA at the sn-2
position (A) whereas PE species containing MUFA (labeled in boxes) are highly enriched in
brain tissues.
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Fig. 2.

Relative contents of major species of phosphatidylethanolamine in the brain (A), heart (B),
kidney (C), and liver (D). (data are presented as mean ± standard deviation, n=6). Closed bar
=MUFA, open bar =PUFA.
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Fig. 3.

Author Manuscript

MS/MS spectra of PE species with m/z 742.8 from the brain (A) and the heart (B), and PEP
species with m/z 701.9 from the brain (C) and the kidney (D). The peak at 478
corresponding to octadecenoyl glycerol and the peaks at 281 corresponding to 18:1 confirm
the structure as PE(18:1/18:1) (A). The peak at 480 corresponding to octadecanoyl glycerol
and the peaks at 279 and 283 corresponding to 18:0 and 18:2 confirms the structure as
PC(18:0/18:2) (B). The peak at 436 corresponding to hexadecenyl glycerol and the peak at
281 corresponding to 18:1 confirm the structure as PEP(16:0/18:1). The peak at 418 is
dehydrated form of 436 and the peak at 255 is from 281-CO2. (C). The peaks at 436 and 281
confirms the structure of the major species as PEP(16:0/18:1), and the peak at 438
corresponding to hexadecanyl glycerol and the peak 279 corresponding to18:2 confirms the
structure of the minor species as plasmanyl PE(16:0/18:2) (D).
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Fig. 4.

Relative contents of plasmenyl phosphatidylethanolamine in the brain (A), heart (B), kidney
(C), and liver (D) (data are presented as mean ± standard deviation, n=6). Closed bar
=MUFA, open bar =PUFA.
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Fig. 5.

MS spectra of PC from brain (A), heart (B), kidney (C), and liver (D) tissues. Three most
abundant PC species in brain tissue contain saturated fatty acid or mono unsaturated fatty
acids (labeled in boxes, 779, PC(16:0/16:0); 805, PC(16:0/18:1); and 833, PC(18:0/18:1)
(A). Major PC species in liver tissue contain PUFA (D).
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Fig. 6.

Relative contents of major species of PC from the brain (A), heart (B), kidney (C), and liver
(D) (data are presented as mean ± standard deviation, n=6). Closed bar =Saturated or
MUFA, open bar =PUFA.
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Fig. 7.

MS spectra of PS from brain (A), heart (B), kidney (C), and liver (D) tissues. PS species
containing MUFA (788.7, PS(18:0/18:1) is significantly higher in the brain than other
tissues.
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Fig. 8.

Relative contents of major species of PS from the brain (A), heart (B), kidney (C), and liver
(D) (data are presented as mean ± standard deviation, n=6). Closed bar =MUFA, open bar
=PUFA.
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Fig. 9.

Relative contents of major species of PI and PG from the brain, heart, kidney, and liver (data
are presented as mean ± standard deviation, n=6).
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Fig. 10.

Mass spectra of CL from brain (A), heart (B), kidney (C), and liver (D) tissues. CL(18:2)4 is
the major species in the heart, kidney, and liver but only a minor species in the brain.
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Fig. 11.

Heatmap representation of phospholipid profiles in the brain, heart, kidney, and liver
generated by Metaboanalyst software v.3.0. Sample intensities were scaled using Pareto
scaling (high [red] and low [blue]). Heatmap trends show that the contents of phospholipid
containing MUFA are higher in the brain than in other tissues.
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53.9 ± 5.3

22.0 ± 6.0

24.7 ± 5.5

22.8 ± 3.3

brain

heart

kidney

liver

PE

31.2 ± 3.8

18.0 ± 4.2

17.0 ± 5.0

30.5 ± 4.5

PC

1.21 ± 0.32

2.31 ± 0.45

0.48 ± 0.14

7.78 ± 0.93

PS

8.52 ± 1.1

5.31 ± 1.3

2.74 ± 0.86

5.13 ± 0.76

PI

0.01 ± 0.00

0.02 ± 0.01

0.17 ± 0.06

0.02 ± 0.01

PG

1.08 ± 0.21

1.38 ± 0.35

2.31 ± 0.66

0.27 ± 0.15

CL

64.9 ± 8.6

51.7 ± 11.3

44.7 ± 12.6

97.6 ± 21.6

total
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Concentration of each class of phospholipids in whole tissues (nmol/mg tissue, n= 4)
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Table 2

Molecular composition of major phospholipids characterized by MS/MS

Author Manuscript
Author Manuscript

brain

heart

kidney

liver

715

16:1/18:1

16:0/18:2

16:0/18:2

16:0/18:2

717

16:0/18:1

16:0/18:1

16:0/18:1

739

16:0/20:4

16:0/20:4
18:2/18:2

16:0/20:4

16:0/20:4

743

18:1/18:1

18:0/18:2

18:0/18:2

18:0/18:2

745

18:0/18:1

18:0/18:1

763

16:0/22:6

16:0/22:6

18:2/20:4
16:0/22:6

16:0/22:6
18:2/20:4

765

18:1/20:4
16:0/22:5

18:1/20:4
16:0/22:5

18:1/20:4

18:1/20:4
16:0/22:5

767

18:0/20:4

18:0/20:4

18:1/20:4

18:1/20:4

773

18:0/ 20:1

789

18:1/22:6

791

18:0/22:6

18:0/22:6

18:0/22:6

795

18:0/22:4

PE

18:1/22:6
18:0/22:6

PEP
701

16:0/18:1

16:0/18:1
m16:0/18:21

723

16:0/20:4

16:0/20:4

16:0/20:4

727

18:1/18:1

18:0/18:2

18:0/18:2

729

18:0/18:1
16:0/20:1

737
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m18:0/18:2
18:0:18:1

m18:0/18:2

16:1/20:4
16:0/20:5

16:1/20:4
16:0/20:5

747

16:0/22:6

16:0/22:6

16:0/22:6

749

18:1/20:4

18:1/20:4
16:0/22:5

18:1/20:4

751

18:0/20:4
16:0/22:4

18:0/20:4

18:0/20:4

753

18:0/20:4
m18:0/20:4

757

18:0/20:1

773

18:1/22:6

18:1/22:6

775

18:0/22:6

18:0/22:6

18:0/22:6

779

18:0/22:4

16:0/16:0

16:0/16:0

18:0/22:6

PC
779

16:0/16:0

Author Manuscript

803

16:0/18:2

16:0/18:2

805

16:0/18:1

16:0/18:1

16:0/18:1

16:0/18:1

827

16:0/20:4

16:0/20:4

16:0/20:4

16:0/20:4

831

18:1/18:1

18:0/18:2

18:0/18:2

18:0/18:2

833

18:0/18:1
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brain

heart

kidney

liver

16:0/22:6

16:0/22:6

16:0/22:6

16:0/22:6
18:2/20:4

853

18:1/20:4
16:0/22:5

855

18:0/20:4

18:0/20:4

18:0/20:4
16:0/22:4

18:0/20:4

879

18:0/22:6

18:0/22:6

18:0/22:6

18:0/22:6
18:1/22:5

PS
783

16:0/20:4

787

18:1/18:1

18:0/18:2

18:0/18:2

789

18:0/18:1

18:0/18:1

18:0/18:1

809

Author Manuscript

811

18:0/20:4

817

18:0/20:1

835

18:0/22:6

839

18:0/22:4

18:0/20:4

18:0/20:5
18:1/20:4

18:0/20:5

18:0/20:4

18:0/20:4

18:0/22:6

18:0/22:6

PI
834

16:0/18:2

836

16:0/18:1

858

16:0/20:4

862

16:0/20:4

16:0/20:4

16:0/20:4

18:0/18:2

Author Manuscript

882

16:0/22:6

884

18:1/20:4

18:1/20:4

886

18:0/20:4

18:0/20:4

18:0/20:4

910

18:0/22:6

18:0/22:6

18:0/22:6

912

16:0/22:6
18:1/20:4
16:0/22:5
18:0/20:4

18:0/22:5

PG
722

16:0/16:0

746

16:0/16:0

16:0/16:0

16:0/18:2

16:0/18:2

16:0/18:2

16:0/18:1

16:0/18:1

748

16:0/18:1

16:0/18:1

770

16:0/20:4

16:0/20:4

774

18:0/18:2

16:0/20:2
18:0/18:2

1

m, plasmanyl PE
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